Search Results

Pharmacy benefit manager Express Scripts announced Tuesday it has filed a lawsuit in federal court in Missouri against the Federal Trade Commission for its “unfair, biased and erroneous” July report on the industry.

Express Scripts, the pharmacy benefits services business of The Cigna Group’s Evernorth, is making it easier for people to access a broader range of care services at independent pharmacies.

Phathom Pharmaceuticals, Inc. today announced the placement of VOQUEZNA® (vonoprazan) tablets for the treatment of adults with Erosive Esophagitis, commonly referred to as Erosive GERD (gastroesophageal reflux disease), and relief of heartburn associated with Erosive Esophagitis on the Express Scripts national formularies, effective immediately.

Lexicon Pharmaceuticals, Inc. announced that Express Scripts, the pharmacy benefits management business of The Cigna Group’s Evernorth, has determined that it will place INPEFA on its Premier Access and Premier Performance national formularies for Medicare patients on November 1, 2023.

Lexicon Pharmaceuticals, Inc. announced that Express Scripts, the pharmacy benefits management business of The Cigna Group’s Evernorth, has determined that it will place INPEFA on its Basic and High Performance formularies for commercially insured patients as of, November 1, 2023, and in addition to the previously reported Premier Access and Premier Performance national formularies for Medicare patients.

Express Scripts announced that as part of its commitment to driving greater affordability for clients and people living with inflammatory conditions, it will add three additional biosimilars to its National Preferred Formulary.

The chair of the House Committee on Oversight and Accountability wants the CEOs of CVS Caremark, Express Scripts and Optum Rx to fix statements they made in a hearing last month that contradicted the committee’s and Federal Trade Commission’s findings.

Mirroring fellow pharmacy benefit manager CVS Caremark, Cigna’s Express Scripts is taking Humira off its major commercial formularies starting next year and focusing on more affordable biosimilar options.